Translating biomarkers to clinical practice

被引:0
作者
R H Perlis
机构
[1] Laboratory of Psychiatric Pharmacogenomics,Department of Psychiatry
[2] Massachusetts General Hospital and Harvard Medical School,undefined
来源
Molecular Psychiatry | 2011年 / 16卷
关键词
biomarker; test; diagnostic; genetic; cost-effectiveness; utility;
D O I
暂无
中图分类号
学科分类号
摘要
Biomarkers are the measurable characteristics of an individual that may represent risk factors for a disease or outcome, or that may be indicators of disease progression or of treatment-associated changes. In general, the process by which biomarkers, once identified, might be translated into clinical practice has received scant attention in recent psychiatric literature. A body of work in diagnostic development suggests a framework for evaluating and validating novel biomarkers, but this work may be unfamiliar to clinical and translational researchers in psychiatry. Therefore, this review focuses on the steps that might follow the identification of putative biomarkers. It first addresses standard approaches to characterizing biomarker performance, followed by demonstrations of how a putative biomarker might be shown to have clinical relevance. Finally, it addresses ways in which a biomarker-based test might be validated for clinical application in terms of efficacy and cost-effectiveness.
引用
收藏
页码:1076 / 1087
页数:11
相关论文
共 218 条
[1]  
Rush AJ(2006)Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR Am J Psychiatry 163 1905-1917
[2]  
Trivedi MH(2010)D report Clin Pharmacol Ther 87 356-361
[3]  
Wisniewski SR(2006)Deconstructing the drug development process: the new face of innovation Am J Psychiatry 163 217-224
[4]  
Nierenberg AA(2007)Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD) Arch Gen Psychiatry 64 633-647
[5]  
Stewart JW(2001)Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Clin Pharmacol Ther 69 89-95
[6]  
Warden D(2001)Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Am J Psychiatry 158 848-856
[7]  
Kaitin KI(1986)How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors J Pers Soc Psychol 51 1173-1182
[8]  
Perlis RH(2010)The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations Nat Rev Drug Discov 9 560-574
[9]  
Ostacher MJ(1980)Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Biol Psychiatry 15 449-458
[10]  
Patel JK(1985)Normalization of dexamethasone suppression test: a laboratory index of recovery from endogenous depression Arch Gen Psychiatry 42 1193-1204